BWM
ALXN

Baystate Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Baystate Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2
Closed -$1K – 707
2018
Q1 		$1K Buy
+2
New +$239 ﹤0.01% 650
2017
Q3 		– Sell
-10
Closed -$1K – 698
2017
Q2 		$1K Hold
10
– – ﹤0.01% 653
2017
Q1 		$1K Buy
+10
New +$1.29K ﹤0.01% 617

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baystate Wealth Management's ALXN Position: Q2 2018 in Review

Baystate Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2 shares — an estimated $1K sold.

Baystate Wealth Management first reported a position in ALXN in Q1 2017 and held it in 3 quarters. The position peaked at $1K in Q1 2018. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Baystate Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Baystate Wealth Management sold 2 Alexion Pharmaceuticals shares in Q2 2018, an estimated $1K.
  • Baystate Wealth Management first reported a position in Alexion Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Baystate Wealth Management's Alexion Pharmaceuticals position peaked at $1K in Q1 2018.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Baystate Wealth Management's 13F filing for Q2 2018, filed 17 Jul 2018.